Researchers publishing in the Journal of Translational Medicine described a fratricide-driven approach using unedited CD7 CAR‑T cells to treat T‑cell leukemia. The strategy leverages intrinsic T‑cell interactions to limit CAR‑T self-reactivity without extensive genome editing, simplifying manufacturing and preserving potency in preclinical studies. The paper reports promising activity against T‑cell malignancies while highlighting safety and persistence questions that remain before clinical translation. Authors position the unedited CD7 CAR‑T route as a lower-complexity alternative to extensively edited products, potentially lowering production barriers if safety and off‑target effects are managed.